A61K 38/196
Thrombopoietin
Official title: {Thrombopoietin}
A61K38/196 (Thrombopoietin) appears on 50 US grants and 104 published applications in this corpus.
Search patents in A61K- Granted patents
- 50
- Published applications
- 104
- Assignees
- 57
- Inventors
- 188
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 2 | 0 |
| 2000 | 4 | 0 |
| 2001 | 2 | 1 |
| 2002 | 0 | 2 |
| 2003 | 2 | 3 |
| 2004 | 1 | 5 |
| 2005 | 0 | 1 |
| 2006 | 2 | 5 |
| 2007 | 0 | 2 |
| 2008 | 1 | 2 |
| 2009 | 1 | 5 |
| 2010 | 5 | 8 |
| 2011 | 5 | 8 |
| 2012 | 4 | 4 |
| 2013 | 2 | 8 |
| 2014 | 3 | 6 |
| 2015 | 1 | 4 |
| 2016 | 2 | 5 |
| 2017 | 1 | 3 |
| 2018 | 1 | 2 |
| 2019 | 1 | 5 |
| 2020 | 1 | 5 |
| 2021 | 2 | 5 |
| 2022 | 1 | 5 |
| 2023 | 1 | 2 |
| 2024 | 0 | 5 |
| 2025 | 2 | 1 |
| 2026 | 1 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods of treatment with pegfilgrastim and romiplostim14 Jul 2026US 12,678,484 B2
- Methods of protecting vascular integrity induced by targeted radiation therapy18 Mar 2025US 12,251,424 B2Janssen Pharmaceutica NV
- Process for lyophilized pharmaceutical formulations of a therapeutic protein18 Mar 2025US 12,251,474 B2Amgen Inc.
- Combination inhibiting MEIS proteins14 Mar 2023US 11,602,546 B2Yeditepe Universitesi
- Methods of mitigating toxic effects of vesicants and caustic gas15 Mar 2022US 11,273,203 B2Janssen Pharmaceutica NV
- Use of quinolinone derivative in treatment of immune thrombocytopenia11 Jun 2026US 2026/0158028 A1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Pharmaceutical composition for the treatment of radiation induced toxicity7 May 2026US 2026/0124193 A1Zydus Lifesciences Limited
- Methods for Mitigating Lung Injury in Conjunction with Exposure to Radiation and/or Radiation or Radiomimetic Treatments9 Oct 2025US 2025/0312417 A1Janssen Pharmaceutica NV
- Methods of using glycopolysialylated therapeutic proteins15 Aug 2024US 2024/0269300 A1Xenetic Biosciences, Inc.
- Nk cells or t cells expressing hematopoietic growth factor receptors and methods of use18 Jul 2024US 2024/0238339 A1The United States of America, as represented by the Secretary, Dept. of Health and Human Services
Most cited
By later US patents
- Method and compositions for treatments of cancers104US 6,231,536 B12001
- Antibody therapy71US 7,662,378 B2Immunomedics, Inc. · 2010
- Stable protein: phospholipid compositions and methods51US 5,874,075 AAmgen Inc. · 1999
- Mobilization of peripheral blood precursor cells by .beta.(1,3)-glucan45US 6,117,850 AThe Collaborative Group, Ltd. · 2000
- Therapeutic uses of allogeneic myeloid progenitor cells31US 7,811,815 B2The Board of Trustees of the Leland Stanford Junior University · 2010